Introduction
============

The prefrontal cortex (PFC) is critically involved in many higher brain functions, including cognitive functions and behavioral control, which are altered in schizophrenic patients ([@bib38]; [@bib20]; [@bib74]). Autopsy and neuroimaging studies have revealed the existence of a reduced PFC volume, reduced layer thickness, tight packing of pyramidal neurons and reduced neuropil in the brains of schizophrenic patients ([@bib27]; [@bib61]; [@bib38]). Alterations in key neurotransmitters such as glutamate, GABA, and dopamine (DA) have also been reported in PFC ([@bib38]; [@bib9]; [@bib37]). Moreover, untreated schizophrenic patients show a reduced energy metabolism in the PFC which has been related with negative symptoms ([@bib5]; [@bib54]) yet psychotic symptoms appear associated with hyperactivity of various cortical areas, including the PFC ([@bib14]; [@bib19]; [@bib63]).

Classical antipsychotic drugs are thought to alleviate schizophrenia symptoms by dampening the overactivity of DA at D2 receptor in ventral striatum. In contrast, second generation (atypical) antipsychotics preferentially target serotonin (5-HT) receptors such as 5-HT~2A~, 5-HT~2C~, and 5-HT~1A~ receptors ([@bib11]; [@bib7]; [@bib18]). These receptors are densely expressed in various subfields of the rat PFC, particularly in its medial aspect ([@bib51], [@bib52]). Recent studies have established their presence in a large proportion of PFC pyramidal and GABAergic neurons. In particular, 50--60% of the pyramidal neurons in layers II/III and V of the medial PFC (mPFC) express 5-HT~2A~ and/or 5-HT~1A~ receptors ([@bib4]; [@bib59]).

Anatomical and electrophysiological studies have established the presence of direct afferents from cingulated (Cg), prelimbic (PL), and infralimbic (IL) areas of the PFC to the brainstem monoaminergic nuclei, including the dorsal raphe nucleus (DR) ([@bib3]; [@bib26]; [@bib62]; [@bib50]; [@bib15]) and the ventral tegmental area (VTA) ([@bib67], [@bib66]; [@bib69], [@bib70]; [@bib13]). These nuclei give rise to the ascending serotonergic and dopaminergic innervation of most cortical and limbic brain regions, involved in numerous physiological functions and in severe psychiatric conditions such as major depression and schizophrenia ([@bib12]; [@bib30]; [@bib73]; [@bib75]; [@bib36]; [@bib58]; [@bib71]; [@bib60]).

Previous studies have reported that the systemic administration of 5-HT~2A~ receptor ligands such as DOI (5-HT~2A/2C~ receptor agonist) or M100907 (selective 5-HT~2A~ receptor antagonist) modulates the DA system ([@bib24]; [@bib29]; [@bib41]; [@bib48]; [@bib53]), yet the location of the receptors responsible for these effects was unknown. More recently, it was reported that the local application of DOI in mPFC increased burst firing of DA cells in the VTA and the DA output in the mesocortical DA pathway ([@bib10]). Similarly, local DOI application in the mPFC enhanced the firing rate of DR 5-HT neurons and 5-HT output in rat mPFC ([@bib39]; [@bib4]). These observations suggested that the activity of the ascending cortical DA and 5-HT systems can be modulated by 5-HT~2A~ receptor activation in pyramidal neurons projecting to midbrain.

In the present study, we provide histological support to this hypothesis by using a combination of tract-tracing techniques and subsequent in situ hybridization of 5-HT~2A~ receptor mRNA in PFC sections containing retrogradely labeled neurons projecting to DR or VTA.

Experimental Procedures
=======================

Animals
-------

Male albino Wistar rats (Iffa Credo, Lyon, France) weighing 250--300 g were used in this study. Animals were kept in a controlled environment (12-h light/dark cycle and 22 ± 2 °C room temperature) with food and water provided ad libitum. All experimental procedures used in this study were in strict compliance with the Spanish legislation and the European Communities Council Directive on "Protection of Animals Used in Experimental and Other Scientific Purposes" of November 24, 1986 (86/609/EEC). Animal work was carried out in the animal facilities of the School of Medicine of the University of Barcelona and all protocols used were approved by its Ethical Committee for Animal Research and by the "Departament de Medi Ambient i Habitatge" from the Catalan Government (Generalitat de Catalunya).

Animals were deeply anesthetized with sodium pentobarbital (60 mg/kg ip), and placed in a stereotaxic frame (David Kopf Instruments). Glass capillary tubes were heated and pulled with a Narishige PE-2 pipette puller (Narishige Sci. Inst., Tokyo, Japan), Tips were broken to 30 μm diameter under microscopic control. The micropipettes were then filled with a solution of cholera-toxin B subunit (CTB, 2% in distilled water, List Biological Laboratories, Campbell, CA). CTB was iontophoretically injected into the DR (AP −7.6 to −7.8; L −3.1 with a vertical 30° angle; DV −6.2 to −6.8; *n* = 3) or the VTA (AP −5.6 to −6.0; L −0.5; DV −8.2; *n* = 3). Stereotaxic coordinates were taken from the atlas of [@bib46]. The iontophoretic injections were performed using a 5 μA positive-pulsed direct current for a total of 5 min (7 s on/off for 10 min). After surgery, rats were housed individually. Ten days after surgery, the animals were anesthetized with an ip overdose of sodium pentobarbital and perfused transcardially with 50 mL of calcium-free Tyrode\'s solution (6.8 g/L NaCl; 0.4 g/L KCl; 0.32 g/L MgCl~2~·6H~2~O; 0.10 g/L MgSO~4~·7H~2~O; 0.17 g/L NaH~2~PO~4~·H~2~O; 2.2 g/L NaHCO~3~; 1.1 g/L glucose) containing 0.1% heparin at 37°C, followed by 50 mL of warm (37 °C) and 300 mL of cold (4 °C) fixative (4% paraformaldehyde in 0.1 M phosphate buffer, pH 6.9). After perfusion, the skull was opened and the brain carefully removed and stored for 2 days in a cryoprotective solution (10% sucrose in 0.1 M phosphate buffer, pH 7.4). The brains were then frozen by slow immersion into dry-ice chilled isopentane. Tissue sections, 14 μm thick, were cut on a microtome-cryostat (Microm HM500 OM, Walldorf, Germany), and thaw-mounted onto glass slides pretreated with Histogrip (Zymed Laboratories Inc., San Francisco, CA).

Localization of Injection Sites
-------------------------------

Tissue sections taken at the level of the injection sites (VTA or DR) were incubated during 3--4 days in a humid chamber at 4 °C with a rabbit antiserum anti-CTB (1:1000; Sigma, St Louis, MI) alone or in combination with sheep anti-tryptophan hydroxylase (TPH) antiserum (1:100; Chemicon Intl.) or an anti-tyrosine hydroxylase (TH) monoclonal antibody (1:1000; Diasorin, Stillwater, MN). Then the sections were rinsed in 0.1 M phosphate-buffered saline (PBS) and incubated for 30 min at 37 °C with appropriate combinations of the following antisera (1:500, Molecular Probes, Leiden, NL): AlexaFluor 546-conjugated goat anti-rabbit (for CTB) and AlexaFluor 488-conjugated goat anti-mouse (for TH) or AlexaFluor 488-conjugated donkey anti-rabbit (for CTB) and AlexaFluor 546-conjugated donkey anti-goat (for TPH). Finally, the sections were washed in PBS and coverslipped using Mowiol (Merck, Darmstadt, Germany). The sections were observed and photographed in an epifluorescence microscope (Nikon Eclipse E1000, Nikon, Tokyo, Japan).

In Situ Hybridization Histochemistry Procedure
----------------------------------------------

Sections through the PFC from rats injected with CTB were hybridized with probes against the 5-HT~2A~ receptor mRNA. We used simultaneously 3 oligonucleotide probes complementary to bases 128--170, 1380--1427, and 939--987 (GenBank accession no. NM_017254) ([@bib55]). These probes were synthesized on a 380 Applied Biosystem DNA synthesizer (Foster City Biosystem, Foster City, CA) and purified on a 20% polyacrylamide/8 M urea preparative sequencing gel. The oligonucleotides (2 pmol each) were labeled at their 3′-end with \[^33^P\]α-dATP (\>2500 Ci/mmol; Perkin-Elmer, Boston, MA) using terminal deoxynucleotidyltransferase (Roche Diagnostics GmbH, Mannheim, Germany), and then purified by centrifugation using QIAquick Nucleotide Removal Kit (Qiagen GmbH, Hilden, Germany).

The protocols for in situ hybridization were based on previously described procedures ([@bib68]). Briefly, frozen tissue sections were first brought to room temperature, fixed for 20 min at 4 °C in 4% paraformaldehyde in Dulbecco\'s PBS (1× dPBS: 8 mM Na~2~HPO~4~, 1.4 mM KH~2~PO~4~, 136 mM NaCl, 2.6 mM KCl), washed for 5 min in 3x PBS at room temperature, twice for 5 min each in 1× dPBS and incubated for 2 min at 21 °C in a solution of predigested pronase (Calbiochem, San Diego, CA) at a final concentration of 24 U/mL in 50 mM Tris--HCl pH 7.5, 5 mM ethylenediaminetetraacetic acid. The enzymatic activity was stopped by immersion for 30 s in 2 mg/mL glycine in 1× dPBS. Tissues were finally rinsed in 1× dPBS and dehydrated through a graded series of ethanol. For hybridization, the labeled probes were diluted in a solution containing 50% formamide, 4× SSC (1× SSC: 150 mM NaCl, 15 mM sodium citrate), 1× Denhardt\'s solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 10% dextran sulfate, 1% sarkosyl, 20 mM phosphate buffer pH 7.0, 250 μg/mL yeast tRNA and 500 μg/mL salmon sperm DNA. Tissue sections were covered with hybridization solution containing the labeled probe, overlaid with Nescofilm coverslips (Bando Chemical Ind., Kobe, Japan) and incubated overnight at 42 °C in humid boxes. Sections were then washed 4 times (45 min each) in washing buffer (0.6 M NaCl, 10 mM Tris--HCl pH 7.5) at 60 °C and once in the same buffer at room temperature for 30 min.

The specificity of the hybridization signal obtained with the probes used has been previously established ([@bib52]). These controls included the following procedures: 1) the thermal stability of the hybrids obtained was checked for every probe, 2) for a given oligonucleotide probe, the hybridization signal was completely blocked by competition of the labeled probe in the presence of 50-fold excess of the same unlabeled oligonucleotide, and 3) the distribution of the hybridization signal at the regional and cellular levels obtained with the 3 probes used independently was identical.

CTB Immunohistochemistry on Hybridized Sections
-----------------------------------------------

After the in situ hybridization protocol, tissue sections were kept for 15 min in Tris--HCl buffer (0.10 M pH 7.5) containing 1 M NaCl, 2 mM MgCl^2^·6H2O, and 2% BSA. This buffer was also used in subsequent incubations and washes unless specified. The sections were first incubated for 4 h at 37 °C with rabbit anti-CTB antiserum (1:1000; Sigma, St. Louis, MI). Subsequently the sections were washed 3 times (5 min each) and then incubated 30 min with biotinylated goat anti-rabbit immunoglobulins (1:100, Vector Laboratories). After three 5-min washes, the sections were incubated for one hour in Vectastain Elite ABC solution (Vector Laboratories) in a low salt buffer (0.6 M NaCl, 10 mM Tris--HCl pH 7.5). Sections were then washed 3 times and immersed in a solution of 0.5 mg/mL 3,3′-diaminobenzidine (DAB, Sigma-Aldrich) in Tris--HCl 0.05 M pH 7.5 containing 1 μL/mL H~2~O~2~ until color development (in all cases less than 10 min). The reaction was stopped by 2 rinses in buffer. CTB staining appeared as brown/orange precipitate in the soma and proximal dendrites of retrogradely labeled neurons. The sections were then briefly dipped in 70 and 100% ethanol, air-dried and dipped into Ilford K5 nuclear emulsion (Ilford, Mobberly, Cheshire, UK) diluted 1:1 with distilled water. They were exposed in the dark at 4 °C for 6 weeks and were finally developed in Kodak D19 (Kodak, Rochester, NY) for 5 min, fixed in Ilford Hypam fixer (Ilford), washed, and coverslipped using Mowiol (Merck).

Analysis of the Results
-----------------------

Tissue sections processed for in situ hybridization followed by immunohistochemical detection of CTB were examined in a Nikon Eclipse E1000 microscope (Nikon, Tokyo, Japan). Cell counting was performed manually at the microscope with the help of "analySIS" software (Soft Imaging System GmbH, Germany) in 1--3 coronal sections of each rat corresponding to approximately +3.2 mm from Bregma, according to atlases of the rat brain ([@bib46]; [@bib64]) DAB-labeled cells were considered positive when a dark precipitate was clearly distinguished from background. Only CTB-labeled cells showing great abundance of 5-HT~2A~ receptor mRNA signal (densities of silver grains \>3-fold greater than average background) were considered positive for both markers. Using this procedure, we cannot discard that the number of 5-HT~2A~ receptor-bearing neurons has been somehow underestimated. We preferred this to a false-positive identification of 5-HT~2A~ receptor-expressing neurons. Because the presence of high densities of autoradiographic silver grains might sometimes mask DAB-labeling, cells in the preparations were systematically examined at different focal planes to see CTB-immunoreactivity at lower planes and hybridization signal at upper planes. Micrography was performed using a digital camera (Color View 12) and the software "analySIS" on a Nikon Eclipse E1000 microscope (Nikon) or an Olympus NewCast microscope (Olympus, NL). Digital images were treated with Adobe Photoshop (Adobe Software, Mountain View, CA) to adjust only brightness, contrast and size to make the final figures.

Results
=======

The data reported here correspond to 6 rats in which CTB was microiontophoretically applied into the VTA or the DR (*n* = 3 for each site). In all cases, the applied CTB was confined within the respective nucleus, as shown by the colocalization of the tracer and the markers for dopaminergic neurons of the VTA (TH) and serotonergic neurons of the DR (TPH). [Figure 1](#fig1){ref-type="fig"} shows representative fluorescence microscope images illustrating the localization of CTB in the VTA (1A--C) and the DR (1D--F) of 2 of the rats used in the study. Schematic drawings in [Figure 2](#fig2){ref-type="fig"} illustrate the location of the different microinjections performed in the VTA and DR.

![Double immunolabeling showing the localization of CTB injection sites in the VTA (*A*) TH (red), (*B*) CTB (green), and (*C*) overlay and in the DR (*D*) TPH (green), (*E*) CTB (red), and (*F*) overlay. The images were taken at the fluorescence microscope from rats V1 and D1, respectively, and were merged using the software "analySIS." Scale bar: 100 μm.](cercorbhn204f01_4c){#fig1}

![Schematic drawings of coronal sections through the VTA (*A*) and the DR (*B*) illustrate the precise location of CTB injections (shaded areas) in the different rats used in this study as assessed by CTB immunostaining. Drawings were taken from [@bib64].](cercorbhn204f02_ht){#fig2}

The application of CTB in the DR or the VTA resulted in the labeling of pyramidal neurons in layer V and superficial aspect of layer VI in the mPFC, including the Cg, PL, and IL subdivisions. CTB-labeled neurons were also found in the orbitofrontal cortex (OFC). These cells were located mainly in the ventral OFC of VTA-injected rats whereas they extended more laterally, reaching the agranular insular cortex in rats injected with CTB in the DR. Tracer application in the DR resulted in the labeling of PFC neurons in both hemispheres, whereas the application in the VTA labeled almost exclusively neurons in the ipsilateral hemisphere. [Figure 3](#fig3){ref-type="fig"} shows the schematic location of CTB-retrogradely labeled neurons in the PFC of 2 rats (V2 and D2 in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, respectively) injected with the tracer in the VTA (V2, [Fig. 3*A*](#fig3){ref-type="fig"}) and in the DR (D2, [Fig. 3*B*](#fig3){ref-type="fig"}), respectively. Each dot corresponds to 3 CTB-labeled pyramidal neurons.

###### 

5-HT~2A~ receptor expression in PFC neurons projecting to VTA

  Rat   PFC region      CTB+   CTB+/5HT~2A~+   \% Double-labeled cells
  ----- --------------- ------ --------------- -------------------------
  V1    mPFC            24     10              43
        OFC (ventral)   21     10              45
  V2    mPFC            17     10              59
        OFC (ventral)   14     9               65
  V3    mPFC            90     54              60
        OFC (ventral)   0      0               ---

Note: Values are numbers of CTB-positive neurons in each structure (1--2 sections per rat), as determined by CTB-immunoreactivity (CTB+). CTB-positive neurons that are also positive for the 5-HT~2A~ receptor transcript (CTB+/5-HT~2A~+), were identified by the presence of the 2 markers (see Methods). Only neurons with unambiguous labeling for both markers were considered positive, as in the examples shown in [Figure 3*B*](#fig3){ref-type="fig"}.

###### 

5-HT~2A~ receptor expression in PFC neurons projecting to DR

  Rat   PFC region                                            CTB+   CTB+/5HT~2A~+   \% Double-labeled cells
  ----- ----------------------------------------------------- ------ --------------- -------------------------
  D1    mPFC, ipsilateral[a](#tblfn1){ref-type="table-fn"}    12     7               58
        OFC, ipsilateral[a](#tblfn1){ref-type="table-fn"}     19     13              68
        mPFC contralateral[a](#tblfn1){ref-type="table-fn"}   19     13              68
        OFC contralateral[a](#tblfn1){ref-type="table-fn"}    21     18              86
  D2    mPFC, ipsilateral                                     30     20              67
        OFC, ipsilateral                                      38     30              79
        mPFC contralateral                                    23     14              61
        OFC contralateral                                     30     23              77
  D3    mPFC, ipsilateral                                     19     11              58
        OFC, ipsilateral                                      42     26              61
        mPFC contralateral                                    6      4               67
        OFC contralateral                                     27     22              81

Note: Values are the numbers of CTB-positive neurons in each structure (2 sections per rat), as determined by CTB-immunoreactivity (CTB+). CTB-positive neurons that are also positive for the 5-HT~2A~ receptor transcript (CTB+/5HT~2A~+), were identified by the presence of the 2 markers (see Methods). Only neurons with unambiguous labeling for both markers were considered positive, as in the examples shown in [Figures 4*B*](#fig4){ref-type="fig"} and [5*B*](#fig5){ref-type="fig"}.

CTB application was aimed at the midline in the DR. However, the micropipette entered the brain with an angle of 30° to avoid the sinus. Thus, we use the term ipsilateral to refer to the brain hemisphere where the micropipette first entered the midbrain.

![Schematic drawings of coronal sections through the PFC illustrating the localization of CTB-retrogradelly labeled cells after tracer injections in the VTA of rat V2 (*A*) and the DR of rat D2 (*B*). Every dot represents 3 labeled cell bodies. (*A*) CTB injections in the VTA only labeled cell bodies in the ipsilateral (i) mPFC (including Cg, PL, and IL) and medial (ventral) part of the OFC. (*B*) CTB injections in the DR labeled cell in the mPFC and OFC of both ipsilateral and contralateral (c) hemispheres. Drawings were taken from [@bib46].](cercorbhn204f03_lw){#fig3}

[Figure 4](#fig4){ref-type="fig"} shows 5-HT~2A~ receptor mRNA labeling in VTA-projecting neurons in the mPFC. The presence of the 5-HT~2A~ receptor mRNA was established by dense clusters of silver grains, clearly distinguishable from background. As previously observed ([@bib4]; [@bib59]), a large proportion of cells in the Cg, PL, and IL subdivisions of the PFC were found that contained the 5-HT~2A~ receptor transcript, mainly in layers II/III and V. No 5-HT~2A~ receptor-positive cells were found in layer I and a lower abundance of 5-HT~2A~ receptor-positive cells was observed in layer VI compared with layers III--V. In occasions, the density of silver grains made difficult the detection of CTB-immunoreactivity. In these cases, and because CTB-immunoreactivity and silver grains are localized at different depths of the tissue preparation, a careful inspection of individual cells was performed by examining different planes of the preparation, which contain the CTB signal (lower plane) and the emulsion for in situ hybridization (upper plane). [Table 1](#tbl1){ref-type="table"} shows the number of CTB-positive cells and the percentage of double-labeled cells in the mPFC and ventral OFC of the 3 rats injected with CTB in the VTA. The percentage of CTB-positive cells that expressed 5-HT~2A~ receptors in the mPFC was rather high and homogenous (43--60%; 54 ± 6% on average). Two of the rats also exhibited a moderate-high (45--65%) percentage of CTB-positive neurons expressing the 5-HT~2A~ receptor in the ventral OFC. No unambiguous CTB-positive cells could be detected in the third animal. It is likely that these individual differences depend on the size and precise site of injection of CTB within the VTA. Representative examples of single-labeled (CTB- or 5-HT~2A~ receptor mRNA positive) and double-labeled (CTB- and 5-HT~2A~ receptor mRNA positive) cells are shown at a high magnification in [Figure 4*C*--*E*](#fig4){ref-type="fig"}.

![Colocalization of 5-HT~2A~ receptor mRNA hybridization signal and CTB-immunoreactivity in the mPFC after injection of the tracer in the VTA. (*A*) Clusters of autoradiographic grains corresponding to 5-HT~2A~ receptor mRNA-containing cells are clearly visible in layers II--VI at a low magnification; the strongest signal is found in layer V neurons. The boxed area is shown in (*B*) at a higher magnification. (*B*) CTB-immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red--blue double arrowheads), whereas other cells display only 5-HT~2A~ receptor mRNA signal (blue arrowheads). (*C*) Detail of a CTB-immunoreactive neuron which lacks the hybridization signal. (*D*) Detail of a double-labeled neuron containing CTB-immunoreactivity and a strong 5-HT~2A~ receptor mRNA hybridization signal. (*E*) Detail of a cell profile showing 5-HT~2A~ receptor mRNA signal without CTB-immunoreactivity. Bars: 200 μm (*A*), 30 μm (*B*), 10 μm (*C*--*E*).](cercorbhn204f04_4c){#fig4}

A large proportion of CTB-positive pyramidal neurons in the mPFC and OFC of both hemispheres as labeled by tracer application in the DR also contained 5-HT~2A~ receptor transcripts ([Figs 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). The percentage of CTB-positive cells that expressed 5-HT~2A~ receptors was also high and showed little variability in the 3 rats examined. Representative examples of single-labeled (CTB- or 5-HT~2A~ receptor mRNA positive) and double-labeled (CTB- and 5-HT~2A~ receptor mRNA positive) cells are shown at a high magnification in [Figures 5C--E](#fig5){ref-type="fig"} and [6C--E](#fig6){ref-type="fig"}.

![Colocalization of 5-HT~2A~ receptor mRNA hybridization signal and CTB-immunoreactivity in the mPFC after injection of the tracer in the DR. (*A*) Clusters of autoradiographic grains corresponding to 5-HT~2A~ receptor mRNA-containing cells are clearly visible in layers II--VI at a low magnification. The boxed area is show in (*B*) at a higher magnification. (*B*) CTB-immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red--blue double arrowheads) and in cells lacking hybridization signal (red arrowheads), whereas other cells display only 5-HT~2A~ receptor mRNA signal (blue arrowheads). (*C*) Detail of a CTB-immunoreactive neuron which lacks the hybridization signal. (*D*) Detail of a double-labeled neuron containing CTB-immunoreactivity and a strong 5-HT~2A~ receptor mRNA hybridization signal. (*E*) Detail of a cell profile showing 5-HT~2A~ receptor mRNA signal without CTB-immunoreactivity. Bars: 200 μm (*A*), 30 μm (*B*), 10 μm (*C*--*E*).](cercorbhn204f05_4c){#fig5}

![Colocalization of 5-HT~2A~ receptor mRNA hybridization signal and CTB-immunoreactivity in the OFC after injection of the tracer in the DR. (*A*) Clusters of autoradiographic grains corresponding to 5-HT~2A~ receptor mRNA-containing cells are clearly visible at a low magnification. The boxed area is show in (*B*) at a higher magnification. (*B*) CTB-immunoreactivity (brown precipitate) can be seen in some cells under the hybridization signal (red-blue double arrowheads) and in cells lacking hybridization signal (red arrowheads), whereas other cells display only 5-HT~2A~ receptor mRNA signal (blue arrowheads). (*C*) Detail of a CTB-immunoreactive neuron which lacks of hybridization signal. (*D*) Detail of a double-labeled neuron containing CTB-immunoreactivity and 5-HT~2A~ receptor mRNA hybridization signal. (*E*) Detail of a cell profile showing 5-HT~2A~ receptor mRNA signal without CTB-immunoreactivity. Bars: 200 μm (*A*), 30 μm (*B*), 10 μm (*C*--*E*).](cercorbhn204f06_4c){#fig6}

Discussion
==========

The present results indicate that a substantial proportion (\>50% on average) of pyramidal neurons in the PFC projecting to the midbrain monoaminergic nuclei (DR and/or VTA) contain the 5-HT~2A~ receptor transcript. These results provide anatomical evidence for the existence of a PFC-based, 5-HT~2A~ receptor-mediated distal control of the activity of the ascending dopaminergic and serotonergic systems. From a psychopharmacological perspective, the present data suggest that the interaction of atypical antipsychotics with 5-HT~2A~ receptors in the PFC may decrease the excitatory PFC input onto selected neuronal populations within the DR and the VTA and consequently modulate the activity of the ascending dopaminergic and serotonergic systems.

Methodological Considerations
-----------------------------

5-HT~2A~ receptors are expressed in high densities in PFC ([@bib47]; [@bib52]). More recent data using double in situ hybridization indicate that ∼50--60% pyramidal neurons and ∼20--30% GABAergic neurons in layers II--V of the mPFC contain the 5-HT~2A~ receptor mRNA ([@bib59]). Our results are consistent with these previous observations and show the presence of a high number of 5-HT~2A~ receptor mRNA-expressing cells in the Cg, PL, and IL subdivisions of the PFC, mainly in layers II--V and a lower abundance in layer VI, as observed previously ([@bib52]; [@bib4]; [@bib59]). This demonstrates that the in situ hybridization procedure reliably labeled 5-HT~2A~ receptor-expressing cells in the present experimental conditions, that is, when the hybridization procedure was followed by immunostaining of CTB in the same tissue sections. The present methodology has also been used to determine the presence of 5-HT~4~ receptors in PFC neurons projecting to VTA (Peñas et al., manuscript in preparation). Recent reports have used riboprobes in combination with tract tracers ([@bib28]; [@bib49]; [@bib76]; [@bib8]). The present study indicates that, similarly to riboprobes, oligonucleotides can be reliably combined with tracer immunohistochemistry to identify proteins expressed in relatively low levels, such as monoamine receptors, in projection neurons.

CTB-immunoreactive cells were clearly detected in tissue sections previously treated for in situ hybridization. In the PFC, these cells were exclusively located in the medial and orbital divisions. This distribution agrees well with that reported previously using electrophysiological and tract-tracing methods for DR- and VTA-projecting neurons ([@bib3]; [@bib67]; [@bib66]; [@bib62]; [@bib50]; [@bib31]; [@bib22]; [@bib23]). One possible limitation of the use of CTB is the uptake by damaged fibers of passage close to the application site. This might be a potential confounding factor, particularly for the identification of VTA-projecting neurons, given the proximity of the VTA to the medial forebrain bundle. CTB has been reported to be taken up by fibers of passage ([@bib17]). However, this potential limitation can be minimized by the microiontophoretic application of the tracer, as used herein. This procedure resulted in a tracer distribution within the boundaries of the DR and VTA as observed by the coincidence of the tracer with the TPH and TH immunoreactivity used to label 5-HT and DA neurons, respectively. Nonspecific uptake by damaged fibers of the medial forebrain bundle during CTB application in the VTA would have resulted in labeling of pyramidal neurons in other PFC areas, particularly in the primary and secondary motor areas, that contain the largest proportion of corticospinal fibers of all PFC subdivisions ([@bib22]). Such labeling was not observed in any of the rats, which further supports the specificity of the labeling procedure. Only in one rat (D1), CTB labeled a neighboring area in addition to the DR itself, yet the percentage of double-labeled cells in the PFC was similar to the rest.

The number of CTB-immunoreactive neurons in the mPFC was lower when the CTB immunohistochemistry was conducted in sections previously subjected to in situ hybridization (data not shown). This difference may be attributed to the previous tissue exposure to the hybridizing conditions and/or the high salt concentration used in the immunohistochemical procedure. However, this limitation is unlikely to affect the conclusions of the present study, because we calculated the proportion of 5-HT~2A~ receptor mRNA-positive neurons by reference to the total number of CTB-positive neurons visualized and not vice versa.

Functional Implications
-----------------------

A large body of data in the literature indicates that the activation of 5-HT~2A~ receptors by 5-HT results in neuronal depolarization, reduction of the afterhyperpolarization and increase of excitatory postsynaptic currents and of the discharge rate in pyramidal neurons of the PFC ([@bib6]; [@bib65]; [@bib1], [@bib2]; [@bib4]; [@bib56]; [@bib72]). 5-HT can also activate 5-HT~2A~ receptors in GABA interneurons to increase a synaptic GABA input onto pyramidal neurons ([@bib65]; [@bib77]). Hallucinogens such as DOI DOB or LSD also modify membrane properties of pyramidal neurons and evoke marked cellular and network changes in PFC in vivo and in vitro through the activation of 5-HT~2A~ receptors ([@bib1], [@bib2]; [@bib57]; [@bib72]; [@bib25]; [@bib34]; [@bib16]).

The present histological data, together with these functional observations suggest that activation of 5-HT~2A~ receptors in mPFC pyramidal neurons may increase excitatory inputs onto DA and 5-HT neurons in the VTA and DR, respectively, as well as on GABAergic neurons in both nuclei. This is consistent with the existence of monosynaptic pathways from the PFC to monoaminergic and GABAergic neurons of the VTA and the DR ([@bib3]; [@bib67], [@bib66]; [@bib62]; [@bib69], [@bib70]; [@bib26]; [@bib50]; [@bib15]; [@bib31]; [@bib22]; [@bib23]). It is also consistent with the presence of a high density of layer V pyramidal neurons expressing 5-HT~2A~ receptors ([@bib59]) some of which project to DR and/or VTA, as shown herein. Hence, the systemic administration of 5-HT~2A~ receptor agonists/antagonists can distally modulate the activity of the ascending serotonergic and dopaminergic pathways originated in the DR and VTA, respectively, via PFC 5-HT~2A~ receptors. In support of this view is also the fact that local application of the preferential 5-HT~2A~ receptor agonist DOI in rat mPFC increased the firing rate of a subpopulation of DR 5-HT neurons, increased burst firing of DA neurons in the VTA and elevated the release of both monoamines in PFC ([@bib39]; [@bib10]). Notwithstanding the existence of this direct pathway between the PFC and the VTA involving 5-HT~2A~ receptors, indirect pathways controlling the activity of VTA neurons cannot be excluded. Thus, the electrical stimulation of the mPFC evokes monosynaptic excitatory responses as well as GABA~A~- and 5-HT~1A~ receptor-mediated inhibitory responses in DR 5-HT neurons, indicating that most PFC-driven control of 5-HT neurons occurs via mono- and bisynaptic inputs ([@bib26]; [@bib15]; [@bib31]). However, this is not the case for DA neurons in the VTA which, in addition to short monosynaptic excitations consistent with direct inputs from mPFC ([@bib67]), show complex biphasic responses to mPFC stimulation ([@bib69]). Such biphasic responses might involve alternative pathways such as: 1) PFC → laterodorsal/pedunculopontine tegmental nuclei → VTA, and 2) PFC → nucleus accumbens → ventral pallidum → VTA. These pathways, may also be accountable for an indirect 5-HT~2A~ receptor-mediated control of DA neurons, and both have been shown to modulate DA neuron activity via phasic and tonic inputs, respectively ([@bib21]).

The present results may have functional implications in terms of the interaction between both neurotransmitter systems (e.g., indirect, PFC-mediated vs. direct DR-VTA, interactions mediated by 5-HT~2A~ receptors in the VTA; [@bib42]). They may also be relevant for the mechanism of action of atypical antipsychotic drugs. Most agents of this therapeutic group show greater affinity for 5-HT~2A~ receptors than for DA D2 receptors and produce a greater occupancy of cortical 5-HT~2~ than of subcortical D2 receptors at therapeutic doses ([@bib45]; [@bib40]). Clozapine, the prototypical representative of this group, does not reach---even at very high doses---the 70% of D2 receptor occupancy, considered to be the threshold of therapeutic efficacy for classical antipsychotics ([@bib43]; [@bib32]; [@bib44]). It is unclear how 5-HT~2A~ receptor blockade may contribute to the therapeutic action of atypical antipsychotics. Taken together, the present and previous data suggest that the blockade of 5-HT~2A~ receptors in PFC may attenuate excitatory inputs from PFC to selected neuronal groups in the VTA, thus modulating dopaminergic activity. According to the known connectivity between mPFC and DA and GABA neurons in the VTA ([@bib13]), this should primarily affect dopaminergic neurons projecting back to the mPFC and to limbic areas other than the nucleus accumbens as well as GABA neurons projecting to the latter nucleus. However, the recent demonstration of marked differences in the functional properties of mesocortical vs. mesolimbic DA VTA neurons ([@bib35]) and the fact that VTA GABA neurons may indirectly affect DA neuronal activity make difficult to predict the extent of the 5-HT~2A~ receptor-mediated excitatory inputs on mesolimbic DA neurons in the VTA. Indeed, previous evidence from this laboratory indicated a widespread effect of the local (in mPFC) and systemic application of DOI in a proportion of VTA DA neurons that exceeded by and large the low abundance of mesocortical neurons ([@bib10]). Also, the fact that DOI potentiates the amphetamine-induced release of DA in the nucleus accumbens ([@bib33]) accords with the view that 5-HT~2A~ receptor activation may also affect mesolimbic DA neurons.

In summary, the combined application of in situ hybridization and retrograde tract tracing enabled to show the presence of 5-HT~2A~ receptor mRNA in pyramidal neurons of the medial and orbital divisions of the rat PFC that project to monoaminergic cell groups of the midbrain. This provides anatomical support for previous observations indicating a 5-HT~2A~ receptor-mediated control of DA and 5-HT neurons and raises the possibility that atypical antipsychotic drugs may partly act by reducing excitatory PFC inputs onto subcortical structures, including the midbrain monoaminergic nuclei.
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